Literature DB >> 16900442

Nicorandil opens mitochondrial K(ATP) channels not only directly but also through a NO-PKG-dependent pathway.

Atsushi Kuno1, Stuart D Critz, Michael V Cohen, James M Downey.   

Abstract

Nicorandil, a hybrid of nitrate generator and potassium channel opener, protects ischemic myocardium by opening mitochondrial ATP sensitive potassium (mitoK(ATP)) channels. We recently found that nitric oxide (NO) opened K(ATP) channels in rabbit hearts by a protein kinase G (PKG) mechanism. This study examined whether the NO-donor property of nicorandil also contributes to opening of mitoK(ATP) channels through PKG. MitoK(ATP) channel opening was monitored in adult rabbit cardiomyocytes by measuring reactive oxygen species (ROS) production, an established marker of channel opening. Nicorandil increased ROS production in a dose-dependent manner. The selective mitoK(ATP) channel inhibitor 5-hydroxydecanoate (200 microM) completely blocked ROS production by nicorandil at all doses. The PKG inhibitor 8-bromoguanosine-3',5'-cyclic monophosphorothioate, Rpisomer (Rp-8-Br-cGMPs, 50 microM) shifted the dose-ROS production curve to the right with an increase of the EC(50) from 2.4 x 10(-5) M to 6.9 x 10(-5) M. Rp- 8-Br-cGMPs did not affect the increase in ROS production by the selective mitoK(ATP) channel opener diazoxide while it completely blocked increased ROS production from the NO donor S-nitroso-N-acetylpenicillamine (1 microM). Furthermore ODQ, an antagonist of soluble guanylyl cyclase, blocked nicorandil's ability to increase ROS generation. These results indicate that nicorandil, in addition to its direct effect on the channels, opens mitoK(ATP) channels indirectly via a NO-PKG signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16900442     DOI: 10.1007/s00395-006-0612-5

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  6 in total

1.  Levosimendan attenuates pulmonary vascular remodeling.

Authors:  M Revermann; M Schloss; A Mieth; A Babelova; K Schröder; S Neofitidou; J Buerkl; T Kirschning; R T Schermuly; C Hofstetter; R P Brandes
Journal:  Intensive Care Med       Date:  2011-05-31       Impact factor: 17.440

Review 2.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

3.  Nicorandil improves post-fatigue tension in slow skeletal muscle fibers by modulating glutathione redox state.

Authors:  E Sánchez-Duarte; X Trujillo; C Cortés-Rojo; A Saavedra-Molina; G Camargo; L Hernández; M Huerta; R Montoya-Pérez
Journal:  J Bioenerg Biomembr       Date:  2017-01-04       Impact factor: 2.945

4.  Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats.

Authors:  Wenna Li; Nan Wu; Wenqi Shu; Dalin Jia; Pengyu Jia
Journal:  Exp Ther Med       Date:  2015-10-01       Impact factor: 2.447

5.  Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ning Geng; Li Ren; Lisheng Xu; Deling Zou; Wenyue Pang
Journal:  BMC Cardiovasc Disord       Date:  2021-10-10       Impact factor: 2.298

6.  Nicorandil decreases oxidative stress in slow- and fast-twitch muscle fibers of diabetic rats by improving the glutathione system functioning.

Authors:  Sarai Sánchez-Duarte; Sergio Márquez-Gamiño; Rocío Montoya-Pérez; Erick Andrés Villicaña-Gómez; Karla Susana Vera-Delgado; Cipriana Caudillo-Cisneros; Fernando Sotelo-Barroso; Ma Teresa Melchor-Moreno; Elizabeth Sánchez-Duarte
Journal:  J Diabetes Investig       Date:  2021-02-20       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.